Supplemental Data
Figure S1, related to Table 1. Amplified and random genes screened. (A) This table shows the chromosomal location (NCBI Assembly hg16) of the 29 recurrent HCC amplicons, the total number of RefSeq protein-coding genes within the amplicon, the total number of genes screened in the oncogenomic cDNA assay, and the identity of the screened genes. Genes confirmed as tumorpromoting are in bold type. (B) This table shows the 35 genes chosen at random to be screened in the cDNA assay. The one gene that was found to be tumor-promoting is in bold type. The DNA copy number and relative expression of FGF19 for sixteen primary breast tumors was determined by realtime PCR (TaqMan). Fold-expression is relative to the average of three normal breast samples and DNA copy number is relative to two normal human DNA samples. (B) We performed a query of the three genes FGF19, CCND1, and ORAOV1 using a database of DNA copy number and corresponding RNA expression for 116 tumor and human cancer cell line samples from four different tumor types. Shown is the correlation coefficient of DNA copy number and RNA expression that was created using array data generated as described in Experimental Procedures. 19K4 & 19K5) and CCND1 (D1K2 & D1K4) relative to a shRNA against luciferase (control). All shRNAs relative to control are significant (p<0.001). The combination of D1K2 and 19K4 relative to either alone is not significant (p=0.5836 and p=0.4529, respectively) (n=3, error bars denote ± SD). (C) Subcutaneous tumor growth in nude mice of JHH-7 cells infected with indicated shRNAs. The combination of D1K2 and 19K4 is significant relative to D1K2 alone (p<0.05), but not to 19K4 alone (p=0.1905) (n=10 injections, error bars denote ± SD).
Supplemental Experimental Procedures
Genomic analysis DNA copy number profiling for all primary tumor samples and most HCC cell lines was performed by ROMA, a form of comparative genomic hybridization described previously (Lucito et al., 2003 ). An additional 8 HCC cell lines (JHH-1, JHH-2, JHH-4, JHH-5, JHH-6, HLE, Huh-7, and Li7) were profiled for DNA copy number using the Genome-Wide Human SNP Array 6.0 (Affymetrix); these data were used to determine the amplification status of CCND1/FGF19 but were not included in other analyses. For analyses using ROMA data, log intensity ratios were normalized and then segmented to define copy number alterations relative to reference as described (Hicks et al., 2006) . To determine whether or not a given genome segment was amplified or deleted in a tumor, we first determined which segments were not altered (near the ground state) by applying a Gaussian mixture model-based clustering algorithm to the median copy number ratios. We defined the ground state using the smallest group of clusters whose centers were closest to 1 and whose segments comprised over 50% of the autosomal genome. Next, because normal genomes contain many copy number variations (CNVs), and to avoid mistaking these as recurrent cancer lesions when an unrelated normal DNA was used as reference, regions of common copy number variation were filtered from the segmented profiles as described (Hicks et al., 2006) . Frequency plots were generated from masked data. Gene expression profiling for 13 primary HCCs and 10 HCC cell lines was performed with NimbleGen Gene Expression arrays using conditions recommended by the manufacturer, and quantile normalization intensities were converted to log2 ratios by comparing values obtained with HCC samples to those obtained with universal reference RNA (Stratagene). Pearson correlation coefficients for assessing the relationship between RNA levels and DNA copy number were computed for each gene after log2 transformation of the segmented DNA copy number value. In addition to the 23 HCC samples, 93 tumor and cancer cell line samples from melanoma, breast, and lung cancers were profiled for DNA copy number and RNA expression using the same platforms, and the resultant data were imported into a MySQL database (S.P., unpublished).
Focal copy number alteration (FCNA) scores
FCNA scores incorporate the size of copy number alterations to favor smaller lesions, and are computed separately for deletions and amplifications (the following explanation is for amplifications). For each tumor profile, the FCNA amplification measure at a given genomic position on the array is the reciprocal of the length of the amplified segment (if any). This is summed over a set of cancer profiles, giving us a FCNA statistic. To incorporate recurrence into the FCNA statistic, and also to guard against rare copy number polymorphisms or small random alterations of copy number affecting the statistic, we perform bootstrap sampling to obtain a distribution of the statistic. For each gene we report the value of the median of the statistic, similar to the value of the statistic if the narrowest event covering each genomic position on the array was discarded.
Further information on the construction of the amplicon-focused and randomly selected cDNA libraries
To generate the randomly selected cDNAs, we generated a list of 18,683 unique human genes from the NCBI reference sequence database, assigned to them a randomly generated numerical rank, and obtained the first 35 expression plasmids that were available in the pCMV-SPORT6 vector. All of the full-length cDNAs were then subcloned into puromycin-resistant retroviral vectors. Two different receiving retroviral vectors were constructed for this purpose, both modified from pMSCVpuro (Clontech). For one of the new receiving vectors, the coding sequence of RBM3 was amplified from an original MGC plasmid with PCR primers, creating BglII-SalI sites at the 5' end and NotI-EcoRI sites at the 3' end. The BglII-EcoRI digested insert was cloned into pMSCVpuro, creating a vector such that the inserts from pCMV-SPORT6 cDNA plasmids with SalI 5' sites and NotI 3' sites could be transferred into the pMSCVpuro derivative. A similar strategy was followed to create a pMSCVpuro derivative that could be used to transfer inserts from pCMV-SPORT6 cDNA plasmids with either EcoRI or EcoRV 5' sites and NotI 3' sites. With these two pMSCVpuro derivatives, inserts from the 150 pCMV-SPORT6 cDNA clones were transferred into retroviral vectors. All plasmids were verified by DNA sequencing.
Other plasmid constructions
For oncogene cooperation assays utilizing CCND1, its cDNA was inserted into the retroviral pMSCVhygro vector (Clontech). Retroviral shRNA constructs designed against CTNNB1 (catalog #TG313664) were purchased from OriGene Technologies. For FGF19 and CCND1, four specific 19-mers were designed using BIOPREDsi algorithms (Huesken et al., 2005) and extended two base pairs at the 5' end and one at the 3' end, to create 22-mers. miR30 design shRNAs were synthesized by incorporating "prebind", "loop" and "postbind" sequences into the DNA oligos (using tools developed by Gregory Hannon's laboratory, Cold Spring Harbor Laboratory (codex.cshl.edu). Using PCR, the oligos were amplified using universal primers to add XhoI 5' sites and EcoRI 3' sites to allow cloning into the mir30 vector MLP retroviral vector. Knockdown efficiency was determined by Western blotting.
Tumorigenicity significance tests
The background rate of tumorigenicity as assayed by subcutaneous injections into nude mice for the p53 
Cell culture assays and retroviral infections
For testing the effect of the monoclonal anti-FGF19 antibody on proliferation of HCC cell lines, cells were seeded in duplicate at 5,000 to 10,000 cells per well in 24-well plates. The day after plating, monoclonal anti-FGF19 antibody 1A6 was added at 100 μg/mL and 2-fold dilutions over 6 concentrations were performed to generate a dose-response curve.
Control wells without drug were also seeded. Cells were counted on Day 1 (when drug was added) as well as Day 7 (when the experiment ended). After trypsinization, cells were placed in isotonic solution and counted immediately using a Coulter Z2 particle counter For testing the clonogenicity of HCC cell lines and their derivatives, cells were plated in triplicate in 6-well tissue culture plates at low density (500-1000 cells/well). After 2 to 3 weeks of growth, depending on the individual cell line, the colonies were fixed in methanol and stained with 0.5% crystal violet for 15 minutes, and then washed twice with water before photography. To quantify the growth, the wells were solubilized overnight with 1 ml of 1% SDS before quantitative absorbance readings at 595nm.
For analyzing TCF reporter activity in human HCC cell lines, cells were transfected with a mixture of inducible TCF/LEF-responsive firefly luciferase construct and constitutively expressing renilla luciferase construct (SABiosciences). 48 hours later, cells
were either lysed and luminescence measured (Dual-Luciferase Reporter Assay System, Promega), or treated with 250 ng/mL recombinant FGF19 for 24 hours, followed by lysis and reading.
For retroviral infections, BING amphotropic packaging cells were transfected with 4 μg of retroviral plasmid and 2 μg of helper plasmid in 60-mm dishes using the Profection® Mammalian Transfection System (Promega). After 48 hours, viral supernatant was filtered, supplemented with 4 μg/mL polybrene and added to the target cells. This infection procedure was repeated after 4 hours. Selection was started 48 hours after the last infection, using puromycin or hygromycin.
Immunohistochemistry and immunoblotting
Histopathological evaluation of murine liver carcinomas was performed by an experienced pathologist (H.Y.) with paraffin-embedded liver tumor sections stained with hematoxylin and eosin (H&E). GFP antibody (Cell Signaling) and PCNA antibody (Cell Signaling) staining was performed via standard protocols on paraffin-embedded liver tumor sections.
Western blotting was performed according to standard methods. Antibodies used were to actin (Abcam), active β-catenin (Millipore), β-catenin (BD Biosciences), MAPK 1/2 (Cell Signaling), phospho-MAPK 1/2 (Cell Signaling), cyclin D1 (Abcam) and FGF19 (Abcam).
Functional Enrichment Analysis for Oncogenicity Prediction
Functionally enriched annotation clusters within the full 124 candidate gene set were identified using the online functional annotation tool NIAID/NIH DAVID (http://david.abcc.ncifcrf.gov) (Dennis et al., 2003) . Subsequently, each of the resultant subgroups of candidate genes enriched for a given gene ontology (GO) term, pathway or other functional category was tested for the presence of a significant over-or underrepresentation of tumor-promoting genes using a two-tailed Fisher's exact test.
GRAIL Analysis for Oncogenicity Prediction
The Gene Relationships Across Implicated Loci (GRAIL) online tool from the Broad Institute (http://www.broadinstitute.org/mpg/grail/) (Raychaudhuri et al., 2009 ) was utilized to examine the 29 commonly amplified regions which contained all 124 candidate genes.
GRAIL identified all genes within the selected regions and computed raw p value scores for each gene. The significance score is a measure of the relatedness of the given gene to all other genes within the query set as determined by a text-based similarity metric from a comprehensive search of all PubMed abstracts published prior to December 2006. A Student's t-test was performed assess whether or not the 18 tumor-promoting genes were more significantly inter-related as compared to the 106 non-oncogenic gene set.
DNA-RNA Correlation in an Independent Dataset
Human Mapping 250K Sty Array (Affymetrix) genotyping data from GEO accession GSE9829, reported in (Chiang et al., 2008) , was downloaded, normalized and segmented using the CBS algorithm implemented in DNA copy package in R. DNA copy number
